Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens

Xiao Liu(Central South University), Guangxun Gao(Xijing Hospital), Zhengcong Cao(Air Force Medical University), Biao Tian(Xijing Hospital), Weijing Jia(Xijing Hospital), Juan Feng(Peking University), Shuangshuang Jia(Xijing Hospital), Xiaoli Xin(Xijing Hospital), Yaya Gao(Xijing Hospital), Yuping Chu(Xijing Hospital), Hailong Tang(Xijing Hospital), Chunyan Zhang(Shanxi Medical University), Na Zhang(Shanghai Institute of Organic Chemistry), Hongjuan Dong(Xijing Hospital), Ziwei Chang(ShanghaiTech University), Yanhua Zheng(Xijing Hospital), Xiangxiang Liu(Nanjing Medical University), Ruifeng Yuan(Xijing Hospital)
Frontiers in Oncology
September 14, 2022
Cited by 10


Related Papers